Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Minoxidil
Drug ID BADD_D01473
Description A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Indications and Usage For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
Marketing Status approved; investigational
ATC Code C02DC01; D11AX01
DrugBank ID DB00350
KEGG ID D00418
MeSH ID D008914
PubChem ID 4201
TTD Drug ID D0Y2CJ
NDC Product Code 73277-002; 82607-002; 83454-404; 0591-5642; 38779-0574; 11673-317; 30142-632; 0113-7798; 41163-798; 41250-749; 49035-905; 56062-798; 57483-540; 57483-542; 63940-385; 64942-2111; 68016-382; 69113-128; 71713-091; 71730-023; 72288-701; 72764-002; 72789-278; 79481-0070; 79903-072; 46204-0159; 54236-020; 11822-0114; 11822-0702; 30142-719; 51316-212; 53489-387; 57483-535; 63940-582; 63981-032; 69968-0031; 69968-0089; 71205-757; 71730-798; 72288-202; 72789-279; 72882-094; 81653-002; 82157-200; 82987-101; 83383-398; 0591-5643; 63934-007; 67438-020; 71052-063; 11509-0798; 11673-157; 11673-189; 11673-382; 11822-0606; 11822-0798; 0113-7202; 41250-202; 41250-428; 51326-160; 59450-211; 0363-0703; 68391-302; 69423-559; 69842-599; 70550-605; 72162-1490; 72484-096; 63629-1085; 65121-101; 68196-032; 71205-490; 71730-000; 72288-129; 72288-294; 72764-001; 81632-408; 82157-100; 82269-607; 40700-0008; 79572-022; 21130-273; 21130-750; 0113-1032; 49035-746; 49884-257; 50663-395; 53489-386; 56062-202; 56062-294; 63629-9299; 63629-9620; 64942-2110; 68084-204; 68391-294; 69113-129; 69423-586; 69842-598; 73277-001; 82429-200; 66219-0004; 67438-015; 11673-632; 11822-1033; 0113-0294; 0113-7129; 0113-7294; 37808-202; 41250-294; 51326-165; 56062-070; 0363-0032; 63629-1086; 0363-9090; 0363-9971; 63940-491; 63940-509; 63981-380; 63981-798; 65121-562; 68196-823; 69282-001; 69423-587; 81653-001; 81653-003; 81653-005; 17337-0027; 49452-4780; 51552-1334; 68981-036; 11673-707; 11822-0202; 11822-1323; 25280-006; 30142-294; 0113-7032; 37808-798; 43353-342; 51316-213; 63629-2230; 63629-2232; 0363-9091; 0363-9973; 63940-202; 69423-558; 69842-797; 70518-3419; 72484-095; 0009-5056; 62991-1105; 64162-0210; 11673-158; 11673-798; 11673-919; 0113-0798; 51326-161; 51672-2129; 55301-094; 56062-322; 59640-000; 59779-294; 0363-9972; 63940-032; 63981-294; 68788-8273; 69282-002; 71713-092; 71713-093; 71713-094; 72288-798; 81653-004; 51927-2885; 73005-0008; 80813-0022; 11673-431; 11822-0115; 41250-798; 42291-619; 49884-256; 51672-2128; 57483-530; 59726-115; 0363-2294; 0363-9970; 65121-102; 68196-469; 69968-0090; 71176-781; 71730-129; 71730-202; 71730-294; 82157-002; 82376-6006; 82376-6007; 0009-5230; 51552-0536; 11822-0129; 11822-1260; 25280-007; 0113-1129; 61269-094; 0363-1129; 0363-2798; 63629-2231; 63629-9433; 68016-006; 68084-205; 69968-0030; 71290-813; 80855-201; 81653-006; 82157-001; 82796-100; 10695-149; 76003-0748; 21130-163; 21130-819; 37808-833; 42291-618; 49035-294; 49539-001; 51326-166; 59450-210; 59726-116; 59779-202
UNII 5965120SH1
Synonyms Minoxidil | Rogaine | Regaine | U 10858 | Loniten
Chemical Information
Molecular Formula C9H15N5O
CAS Registry Number 38304-91-5
SMILES C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sexual dysfunction21.03.02.003; 19.08.05.002--Not Available
Sinus tachycardia02.03.03.0100.002806%
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.0030.000701%
Skin irritation23.03.04.0090.001543%Not Available
Skin striae23.01.05.0020.000701%Not Available
Somnolence19.02.05.003; 17.02.04.0060.001052%
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Suicidal ideation19.12.01.003--
Swelling08.01.03.0150.001403%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.002455%
Tachycardia02.03.02.0070.013398%Not Available
Therapeutic response decreased08.06.01.0160.001052%Not Available
Therapeutic response unexpected08.06.01.0010.001543%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000701%
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Virilism21.10.04.001; 05.05.01.001--
Vision blurred17.17.01.010; 06.02.06.0070.000701%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.007295%
Weight increased13.15.01.006--
Retinal toxicity06.09.03.013; 12.03.01.0360.001403%Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Application site inflammation12.07.01.024; 08.02.01.0240.003577%Not Available
Lymphatic disorder01.09.01.003--Not Available
Alcohol withdrawal syndrome19.07.06.005; 08.06.02.0020.001052%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.003577%Not Available
Blood alkaline phosphatase increased13.04.02.004--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages